K
Kalyani Gampa
Researcher at Novartis
Publications - 4
Citations - 568
Kalyani Gampa is an academic researcher from Novartis. The author has contributed to research in topics: c-Raf & Cancer. The author has an hindex of 4, co-authored 4 publications receiving 426 citations.
Papers
More filters
Journal ArticleDOI
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
Journal ArticleDOI
Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Gisele Nishiguchi,Alice Rico,Huw Tanner,Robert J. Aversa,Benjamin R. Taft,Sharadha Subramanian,Lina Setti,Matthew Burger,Lifeng Wan,Victoriano Tamez,Aaron Smith,Yan Lou,Paul A. Barsanti,Brent A. Appleton,Mulugeta Mamo,Laura Tandeske,Ina Dix,John Tellew,Shenlin Huang,Lesley A. Mathews Griner,Vesselina G. Cooke,Anne Van Abbema,Hanne Merritt,Sylvia Ma,Kalyani Gampa,Fei Feng,Jing Yuan,Yingyun Wang,Jacob R. Haling,Sepideh Vaziri,Mohammad Hekmat-Nejad,Johanna M. Jansen,Valery Polyakov,Richard Zang,Vijay Sethuraman,Payman Amiri,Mallika Singh,Emma Lees,Wenlin Shao,Darrin Stuart,Michael Patrick Dillon,Savithri Ramurthy +41 more
TL;DR: 14 (RAF709) is described, a selective B/C RAF inhibitor, which was developed through a hypothesis-driven approach focusing on drug-like properties, and proved to be soluble, kinase selective, and efficacious in a KRAS mutant xenograft model.
Journal ArticleDOI
Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.
Savithri Ramurthy,Benjamin R. Taft,Robert J. Aversa,Paul A. Barsanti,Matthew Burger,Yan Lou,Gisele Nishiguchi,Alice Rico,Lina Setti,Aaron Smith,Sharadha Subramanian,Victoriano Tamez,Huw Tanner,Lifeng Wan,Cheng Hu,Brent A. Appleton,Mulugeta Mamo,Laura Tandeske,John Tellew,Shenlin Huang,Qin Yue,Apurva Chaudhary,Hung Tian,Raman Mahadevan Iyer,A. Quamrul Hassan,Lesley A. Mathews Griner,Laura R. La Bonte,Vesselina G. Cooke,Anne Van Abbema,Hanne Merritt,Kalyani Gampa,Fei Feng,Jing Yuan,Yuji Mishina,Yingyun Wang,Jacob R. Haling,Sepideh Vaziri,Mohammad Hekmat-Nejad,Valery Polyakov,Richard Zang,Vijay Sethuraman,Payman Amiri,Mallika Singh,William R. Sellers,Emma Lees,Wenlin Shao,Michael Patrick Dillon,Darrin Stuart +47 more
TL;DR: 15 (LXH254, Aversa, R); a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity and was progressed through toxicology studies and is being tested in phase 1 clinical trials.
Journal ArticleDOI
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening.
Lesley A. Mathews Griner,Kalyani Gampa,Toan Do,Huyen Nguyen,David Farley,Christopher Hogan,Douglas S. Auld,Serena J. Silver +7 more
TL;DR: These methods provide a unique protocol for testing compound activity in a high-throughput 3D setting and are a compromise to the highly complex matrix-based systems, which are difficult to screen, and conventional 2D assays.